In North America, sales declined 5% year over year to $321 million in the quarter. Sales in North America decreased, as strong growth in branded products in the United States was outweighed by reduced volumes in Canada due to anticipated inventory destocking. It topped the consensus estimate of $294.1 million. Latin American sales saw a 1% year-over-year increase to $310 million in the reported quarter. Sales in Latin America benefited from the strong growth of the new active ingredients, fluindapyr and Isoflex active. It beat the consensus estimate of $296.1 million. In Asia, revenues declined 17% from the previous year to $159 million. Sales in Asia declined due to lower pricing as well as reduced volume driven by ongoing destocking activity in India. It missed the consensus estimate of $163.7 million. EMEA experienced a 29% year-over-year sales increase to $260 million in the reported quarter.